About Actavis + Warner Chilcott
On October 1, 2013, Actavis (NYSE: ACT) announced the acquisition of Warner Chilcott plc, creating an $11 billion leading specialty pharmaceutical company with over $3 billion in pro forma sales. The combination capitalizes on the complementary specialty pharmaceuticals strengths and market positions of the two organizations, building a leader in Women’s Health and Urology, as well as a company with important positions in Gastroenterology and Dermatology.
For more information about the acquisition, please visit the Investor section.
For medical or product related questions for Warner Chilcott manufactured U.S. products, call +1-800-521-8813
For jobs, please visit the Careers section.